GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Cash Payments for Deposits by Banks and Customers

InnoCare Pharma (HKSE:09969) Cash Payments for Deposits by Banks and Customers


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Cash Payments for Deposits by Banks and Customers?

Cash Payments for Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


InnoCare Pharma (HKSE:09969) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Cash Payments for Deposits by Banks and Customers
Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.